Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials
Arrowhead plans sNDA filing by end of 2026.
/ 493 items
#XY Event-Driven Stocks↓
Repligen Acquires BioLife Solutions for $1.5 Billion to Strengthen Cell and Gene Therapy Leadership
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.
Dyne Therapeutics Prices Upsized $375 Million Public Offering to Fuel Muscle Disease Pipeline
Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.
Celldex Discontinues Barzolvolimab Development in Prurigo Nodularis After Phase 2 Failure
Celldex discontinues barzolvolimab development in prurigo nodularis after its Phase 2 study failed to meet the primary endpoint and key secondary endpoints.
PolyPid Secures $320 Million Partnership with Azurity for D-PLEX100 in U.S. and Canada
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
Jupiter Neurosciences Expands CNS Pipeline with ALA-002 Licensing Deal Worth Up to $100M
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.